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Background
In late 2018, the International Livestock Research Institute 
(ILRI) received funding from GALVmed for a research 
project for the development of a subunit vaccine for African 
swine fever. African swine fever is a disease that is present 
in approximately 26 countries in Africa where it poses a 
problem for pig farmers due to the frequent wipeout of 
herds, which happens regularly in some areas. In addition, the 
disease has grown to pandemic proportions in Europe and 
Asia, including China.
There is no vaccine against African swine fever virus (ASFV) 
and current control is based on culling and biosecurity 
measures. Therefore, a vaccine could significantly contribute 
to this control and alleviate the problems for African 
farmers.
The disease
African swine fever (ASF) is a devastating hemorrhagic pig 
disease originating from Africa, first described in Kenya in 
1921. It is currently a major problem in Eastern Europe, 
Asia, China and India where it has spread since it escaped 
to Georgia from Africa in 2007 (Iglesias et al. 2017). African 
swine fever virus (ASFV) is present in about 26 countries in 
Africa, where it poses a serious constraint for pig farmers 
due to the recurrent wipeout of whole pig herds.  
There is no vaccine; therefore, control of the disease is 
dependent on biosecurity and culling of animals. The virus 
infects domestic pigs, wild boars in Europe and Asia and wild 
pigs (i.e. warthogs and bush pigs) in Africa. It is transmitted 
by the soft ticks of the Ornithodores genus in Africa. The 
transmission system is very complex with several farm risk 
factors associated such as, lack of fences and routine cleaning 
of pens (Dione et al. 2017). This complex transmission system 
complicates the control measures.
The virus is a large DNA virus belonging to the Asfaviridae 
family, sharing some similarities with the pox viruses. It 
encodes between 151 and 167 genes depending on the 
isolate. ASFVs are divided into 24 genotypes, all of which have 
been detected in Africa (Quembo et al. 2018). 
The project
One of the goals in the project is to identify antigens from 
ASF which are responsible for the immunity seen using the 
whole virus for vaccination. It has been shown previously that 
modified viruses by deletion of genes can confer immunity. 
Therefore, an attenuated version of ASF isolate was used 
for immunization of pigs followed by peptide screens using 
overlapping peptides (pieces of protein) covering the whole 
virus. The ASF virus which was used was isolated at the 
border between Kenya and Uganda during an outbreak and 
was determined as a genotype IX isolate (Gallardo et al.  
2007 and Onzere et al. 2018). The virus had a deletion of one 
gene called the CD2v gene, which was generated in another 
project.
Three groups of pigs (including European and Kenyan local breed 
pigs, 22 animals in total) were immunized with the modified 
live virus followed by testing of immune cells. Cells were either 
white blood cells (PBMC) or a fraction of these, the CD8 cells, 
which are known as killer cells. They recognize virus-infected 
cells and kill them. The recognition of the infected cells happens 
due to small pieces of protein (peptides) of the virus, which are 
located on the outside of the infected cells. These peptides can 
be recognized by the immune cells and get killed.
In order to determine these peptides which are recognized 
by the immune cells, the cells are cultured together with 
pools of known peptides from the virus. If the cells recognize 
them, they will produce a substance called interferon-gamma 
(IFN-γ). That can be measured in an assay called enzyme-
linked immunospot (ELISpot) assay.
The cells from the three groups of pigs were tested in 
ELISpot for recognition of peptide pools corresponding to 
each gene of the virus. Of the 217 peptide pools tested, 153 
pools were recognized by PBMC of at least one animal (2.8 
animals/pool  +/- 3.6, range 1–17 animals) of which 42 pools 
were also recognized by CD8 T cells of at least one animal 
(1.7 animals/pool +/- 1.5, range 1–6). There were 47 pools 
corresponding to 41 genes, which were recognized among 
members of all three groups (6.8 animals/pool +/- 3.9, range 
3–17). Among these highly immunogenic genes, there were 
known immunogenic genes, as well as genes that have not 
previously been identified as immunogenic. 
Eleven genes have initially been selected for testing 
immunogenicity and protection against ASF in pigs. The 
selected genes are recognized by cells from 5–17 animals out 
of the 22 pigs for the PBMC. The CD8 cells recognized fewer 
pools with the best antigen recognized by six animals.
The antigens are currently being inserted into viral vectors 
for vaccination of pigs. The viral vectors are human 
adenovirus 5 (AdHu5) and modified vaccinia virus (MVA), 
which are both replication-defective, meaning that they don’t 
multiply after injection. Each pig will receive a pool of AdHu5 
with selected genes from African swine fever. Then, they 
will receive a booster with the recombinant MVA with the 
same antigens inserted as in the AdHu5 vectors. Following 
this immunization, they will be challengd with the virus to 
monitor if the vaccine is effective.
Expected outcome
The first generation ASF vaccine will probably be a live 
attenuated vaccine, whereas a second- generation vaccine 
could be a subunit vaccine, which likely will be far safer. 
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in Africa, where many farmers are discouraged from staying in 
the pig business due to recurrent problems of ASF. A vaccine 
would greatly improve income and livelihoods for African 
farmers, which translates to other actors in the value chain. 
References
1. Dione, M.M., Akol, J., Roesel, K., Kungu, J., Ouma, E.A. et al. 
2017. Risk Factors for African Swine Fever in Smallholder 
Pig Production Systems in Uganda. Transboundary 
and Emerging Diseases. 64(3):872–882. doi: 10.1111/
tbed.12452.
2. Gallardo, C., Ademun, A.R., Nieto, R., Arias, M., Martin, 
E. et al. 2007. Genotyping of African swine fever virus 
(ASFV) isolates associated with disease outbreaks in 
Uganda in 2007. African Journal of Biotechnology 10(17): 
3488–3497.
3. Iglesias, I., Rodríguez, A., Feliziani, F., Rolesu, S. and de la 
Torre, A. 2017. Spatio-temporal Analysis of African Swine 
Fever in Sardinia (2012–2014): Trends in Domestic Pigs 
and Wild Boar. Transboundary and Emerging Diseases, 
64(2): 656–662. https://doi.org/10.1111/tbed.12408.
4. Onzere, C.K., Bastos, A.D., Okoth, E.A.,  Lichoti, J.K., 
Bochere, E.N. et al. 2018. Multi-locus sequence typing 
of African swine fever viruses from endemic regions of 
Kenya and Eastern Uganda (2011–2013) reveals rapid 
B602L central variable region evolution. Virus Genes 
54(1):111–123. doi: 10.1007/s11262-017-1521-4. 
5. Quembo, C.J., Jori, F., Vosloo, W. and Heath, L. 2018. 
Genetic characterization of African swine fever virus 
isolates from soft ticks at the wildlife/domestic interface 
in Mozambique and identification of a novel genotype. 
Transboundary and Emerging Diseases 65(2):420–431. doi: 
10.1111/tbed.12700.
